Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from BioInvent International AB ( (SE:BINV) ) is now available.
BioInvent has sharpened its clinical focus and resource allocation in 2025 to advance its lead oncology assets BI-1808 and BI-1206, pausing earlier-stage programs to maximize the probability of success and near-term value. The company reported improved full-year net sales, reduced losses versus 2024 and a solid cash position, while securing key regulatory designations, new patents and ESG verification, which collectively strengthen its competitive and financial footing.
The year saw promising Phase 2a data for BI-1808 in T-cell lymphoma and in combination with pembrolizumab in ovarian cancer, as well as impressive results for a BI-1206 triplet regimen in relapsed or refractory non-Hodgkin’s lymphoma presented at major medical meetings. Looking ahead, BioInvent is guiding to a series of 2026 data catalysts across CTCL, NHL, solid tumors, NSCLC and uveal melanoma, milestones that could significantly influence its clinical trajectory, partnership potential and value perception among investors and other stakeholders.
Additional developments included orphan drug and fast track designations for BI-1808 in T-cell lymphomas from U.S. and European regulators, validation of the TNFR2 target via Phase 1 data on the paused antibody BI-1910, and updated data on other pipeline assets such as BT-001 and BI-1607. The company also realized non-dilutive value through a royalty sale to XOMA, and proposed two new board members to support its next stage of growth.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK31.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish biotechnology company focused on developing antibody-based immunotherapies for cancer. Its pipeline centers on novel antibodies such as BI-1808, targeting TNFR2, and BI-1206, targeting FcγRIIB, aimed at treating T-cell lymphomas, non-Hodgkin’s lymphoma and solid tumors in combination with established drugs like pembrolizumab and rituximab.
Average Trading Volume: 102,100
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK1.73B
See more insights into BINV stock on TipRanks’ Stock Analysis page.